Community Pharmacy-focused Clinical Assessment Platform (Ph-CAP)

以社区药学为中心的临床评估平台（Ph-CAP）

• 批准号: 10054802
• 金额: $ 42万
• 依托单位: DEM DX LIMITED
• 依托单位国家: 英国
• 项目类别: Investment Accelerator
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10054802
• 关键词: Community; Pharmacy; focused; Clinical; Assessment

DemDX will deliver an urgently needed community pharmacy-focused clinical assessment platform (Ph-CAP).The need is driven by the introduction of the Community Pharmacist Consultation Services (CPCS) to integrate community pharmacy into the urgent care and primary care systems by enabling pharmacists to take referrals from NHS 111 and general practice for minor illness symptoms (e.g., lower back pain, nausea, diarrhoea, cough, headache and migraine, sleeping problems, skins infections, sore throat, etc). The CPCS is one of the biggest workforce shake-ups in the NHS in decades, and brings two significant challenges:* Clinical pharmacists require expanded generalist knowledge across hundreds of conditions, signs, symptoms and "red flags," recognition of patient-specific comorbidities, and awareness of frequently updated gold standard protocols. Clinical pharmacists are urgently calling for tools to support them in their expanded roles.* GP surgeries lack confidence in CPCS. Only 13% of GP surgeries use the scheme -- minimising impact on reducing GP workloads and waiting lists (currently a record 6.84m) and improving patient pathways.Ph-CAP builds upon DemDX's sector-leading clinical reasoning intelligent support platform (CRISP), co-developed via InnovateUK and NIHR-funded engagement in six NHS Trusts. It is a gold standard in support tools for allied health professionals.Ph-CAP will be a revolutionary cloud-based clinical assessment tool, using AI and data to support community pharmacists in better, safer, quicker clinical assessment and treatment or referral decisions. Innovations include:* AI allowing dynamic consideration of complex patterns and associations across 10,000s of symptoms, differentials and "red flags" in validated NICE data.* A data-driven structure enabling community pharmacists to make sense of complex data associations to make safe, consistent decisions, with patient-centric data weighting enabling prioritisation of most probable conditions, driving accuracy of recommendations.* Powered by an 8m-patient Oxford-Royal College of GPs dataset.* Linking to local pathways and protocols to inform best referral options.* Outputs are tailored to community pharmacist competencies, focusing on common minor illnesses, e.g., lower back problems.* Ph-CAP is fully interoperable and can be seamlessly integrated into CPCS pathways.

DemDX将提供一个迫切需要的以社区药房为重点的临床评估平台（Ph-CAP）。社区药剂师咨询服务（CPCS）的引入推动了这一需求，使药剂师能够接受来自NHS 111和全科医生的转诊，治疗轻微疾病症状（如腰痛、恶心、腹泻、咳嗽、头痛和偏头痛、睡眠问题、皮肤感染、喉咙痛等），从而将社区药房纳入紧急护理和初级保健系统。CPCS是NHS几十年来最大的劳动力重组之一，并带来了两个重大挑战：*临床药剂师需要扩展通才知识，涉及数百种疾病、体征、症状和“危险信号”，对患者特定合并症的认识，以及对经常更新的黄金标准方案的认识。临床药师迫切需要工具来支持他们扩大的作用。*全科医生对CPCS缺乏信心。只有13%的全科医生手术使用了这一计划——最大限度地减少了全科医生工作量和等待名单（目前创纪录的684万）的影响，并改善了患者的途径。Ph-CAP建立在DemDX行业领先的临床推理智能支持平台（CRISP）的基础上，该平台是由InnovateUK和nihr资助的六个NHS信托基金共同开发的。它是联合卫生专业人员支持工具的黄金标准。Ph-CAP将是一种革命性的基于云的临床评估工具，利用人工智能和数据支持社区药剂师更好、更安全、更快地进行临床评估和治疗或转诊决策。*人工智能允许在经过验证的NICE数据中动态考虑10,000种症状、差异和“危险信号”之间的复杂模式和关联。*数据驱动的结构使社区药剂师能够理解复杂的数据关联，从而做出安全、一致的决策，以患者为中心的数据加权使最可能的条件优先化，提高建议的准确性。*由牛津-皇家全科医生学院800万患者数据集提供支持。*链接到当地途径和协议，告知最佳转诊选择。*产出是根据社区药剂师的能力量身定制的，重点是常见的小病，例如腰背部问题。* Ph-CAP是完全可互操作的，可以无缝集成到CPCS路径。